No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
Ditschkowski
Markus
M
Elmaagacli
Ahmet H
AH
Trenschel
Rudolf
R
Steckel
Nina K
NK
Koldehoff
Michael
M
Beelen
Dietrich W
DW
D019943:Amino Acid Substitution; D015415:Biomarkers; D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data*; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics* / Q000502:physiology; D053208:Kaplan-Meier Estimate; D020125:Mutation, Missense; D017354:Point Mutation; D011087:Polycythemia Vera / Q000201:enzymology / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D055728:Primary Myelofibrosis / Q000201:enzymology / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D011379:Prognosis; D012008:Recurrence; D012306:Risk; D016019:Survival Analysis; D013920:Thrombocythemia, Essential / Q000201:enzymology / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D014184:Transplantation, Homologous / Q000706:statistics & numerical data; D016896:Treatment Outcome
D015415:Biomarkers; D053614:Janus Kinase 2